pharmaphorum3d
FDA starts review of Lantheus’ generic Lutathera
Lantheus’ generic, called 177Lu-PNT2003, was licensed in December 2022 from Point Biopharma, which was acquired by Eli Lilly last month. Lantheus has worldwide rights to the drug, with the ...
PharmiWeb6d
Top News | Radioligand Therapy Market Set to Reach $13 Billion with ~5% CAGR by 2030
Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...
pharmaphorum3d
Transformative trends with real-world data from early access programmes
7 The orphan drug product Lutathera® (lutetium ((177Lu)) oxodotreotide) to treat adults with somatostatin receptor (SSTR) positive gastroentero-pancreatic neuroendocrine tumours (GEP-NETs ...
oncnursingnews4d
177Lu-PSMA-617 Approved for PSMA+ mCRPC
Indications for 177Lu-PSMA-617 now include taxane-based chemotherapy naive adults with PSMA+ mCRPC. The FDA has expanded the label of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617; Pluvicto) ...
urologytimes4d
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
177Lu-PSMA-617 is now approved for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. The phase 3 PSMAfore trial showed a 59% reduction in radiographic progression or ...